Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers

  • End date
    Jun 15, 2024
  • participants needed
  • sponsor
    Inovio Pharmaceuticals
Updated on 14 October 2022
Accepts healthy volunteers


The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.

Condition Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Treatment Placebo, CELLECTRA™ 2000, INO-4700
Clinical Study IdentifierNCT04588428
SponsorInovio Pharmaceuticals
Last Modified on14 October 2022


Yes No Not Sure

Inclusion Criteria

Judged to be healthy by the Investigator on the basis of medical history, physical examination and vital signs performed at Screening
Able and willing to comply with all study procedures
Screening laboratory results within normal limits
Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human Immunodeficiency Virus (HIV) antibody
Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically significant findings (e.g. Wolff-Parkinson-White syndrome)
Be post-menopausal or be surgically sterile or have a partner who is sterile or use medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until 3 months following last dose

Exclusion Criteria

Pregnant or breastfeeding, or intending to become pregnant or father children within the projected duration of the trial starting with the screening visit until 3 months following last dose
History of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) or chronic bronchitis
Currently participating in or has participated in a study with an investigational product within 30 days preceding Day 0
Previous receipt of any vaccine within 30 days preceding Day 0 or planning to receive any vaccine during the timeframe restricted per the protocol
Previous receipt of an investigational vaccine product for the prevention of MERS
Prior exposure to MERS-CoV or camels
Participants who participate in MERS-201 Part 1 cannot participate in MERS-201 Part 2
Fewer than two acceptable sites available for ID injection and EP considering the deltoid and anterolateral quadriceps muscles
Prisoner or participants who are compulsorily detained (involuntary incarceration)
Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids) prior to dosing. Systemic corticosteroids must be discontinued at least 3 months prior to first dose
Reported active drug or alcohol or substance abuse or dependence
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note